Prostaglandins not only have a role in inflammation, but may also be involved as mediators in the immune response. Drugs which affect prostaglandin synthesis may therefore be potential tools with which to modulate disturbed immunity. These possibilities are discussed with reference to immunity in leprosy, and in particular reversal reactions.
All clinicians are aware of the role of prostaglandins as inflammatory mediators; non-steroidal anti inflammatory agents are crucial drugs in every fo rmulary. Now, too, we are getting used to the idea of aspirin as a powerful antiplatelet agent, with significant effects on mortality from coronary heart disease and stroke. However, there may yet be another role for these drugs, for as the arachidonic acid metabolites are ubiquitous and multifaceted, so their inhibition may have widespread effects. It has been known for over 15 years that prostaglandins (PGs) may modulate the immune response although how important this role is, is not yet clear. In this essay I would like to examine the potential effects ofPGs on one disease, leprosy, and suggest that aspirin and its fe llows may yet have a part to play in its therapy.
Prostaglandin synthesis
PGs are derived from arachidonic acid and its analogues, via an oxidative process. Arachidonic acid is present in the membranes of all cells, normally bound to phospholipid. The first step in PG synthesis therefore is release from the cell membrane through the action of the enzyme phospholipase A2. This enzyme is inhibited by steroids, which therefore present the synthesis of all arachidonic acid metabolites.)
Arachidonic acid available within the cell may then go down two pathways, the lipoxygenase pathway, to form leukotrienes, and the cyclo-oxygenase pathway. Action of the latter enzyme creates an intermediate PGGz from which three main groups are derived, prostacyclin, thrombox ane and the PGE and PGF series. Aspirin, indomethacin and the non-steroidal anti-inflammatory agents (NSAIA's) act on cyclo-oxygenase to inhibit the production of all these metabolites. They are thought to have little action on Iipoxygenase synthesis (perhaps even causing an increase in flux through this pathway as a 'diversion' for arachidonic acid), although recently it has been shown that there may be some inhibition in vitro.z
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The biological functions of the PGs are numerous and beyond the scope of this essay. Prostacyclin and thromboxane have opposing effects on platelet aggregation and vasoconstriction, the fo rmer acting as an antagonist. PGs of the E and F series are pro-inflammatory agents, causing local vasodilatation, increased vascular permeability, and potentiating the action of histamine and bradykinin in causing pain and accumulating oedema.' They are implicated in a number of other body systems, for example as endogenous pyrogen within the hypothalamus, and in renal homeostasis-however, in this essay, it is their involvement in immune regulation which is to be considered.
Prostaglandins in normal immunity
IN VITR O STUDIES
The first report directly suggesting that PGs may act as immunoregulatory agents came in 1971, when Smith and his colleagues noted that PGE 2 inhibited incorporation of radio labelled metabolites into human lymphocytes stimulated by mitogens. These results were then fo llowed by those of a number of other investigators who showed that PGE could suppress in vitro markers of lymphocyte activity, e.g. antibody and Iymphokine secretion.3 However, these results do not prove that PGE is an endogenous mediator of immunosuppression; any cell poison would have the same effect. The fo llowing observations argue in its fa vour:
1 Prostaglandins are produced in vitro in the proliferative response to mitogens. One study3 further narrowed down this role as an immunosuppressant to PGs of the E series. Physiological concentrations of these agents inhibit not only the lymphocyte proliferative response but also E rosetting, cytotoxic T cell and NK cell activity. There is evidence, however, that PGE, may act as an immunostimulant in certain in vitro systems,4 e.g. response to BeG. Thus while the overwhelming balance of evidence is in favour of a suppressive role in most in vitro systems, this experiment reminds us that it is dangerous to extrapolate from one such system to the next, let alone to the whole animal. A related point is that the action of prostaglandins and anti prostaglandins in these studies is commonly restricted to a narrow time window at the beginning of the reaction,3 with minimal effects beyond 24-48 h.
IN VI VO STUDIES
PGs may be present and active in the test-tube, but does this have any relevance to the whole animal? There have been few in vivo studies of PGs in the normal human immune response, although the continuous uncontrolled experiment with the thousands of individuals already taking anti prostaglandin agents would suggest that such effects are likely to be small. This does not mean, however, that they are either (a) insignificant, or (b) irrelevant to the disease state where there may already be a disorder of immune regulation.
There have been a number of experiments in mice which demonstrate enhanced antibody response to antigen challenge in vivo.3 Indeed, as long ago as 1968, Robinson and colleagues demonstrated that mice pretreated with indomethacin had an enhanced ability to resist infections. However, perhaps most relevant of these animal experiments was the observation of one study5 that simultaneous oral administration of indomethacin resulted in a marked increase in skin thickness of the delayed type hypersensitivity (DTH) response to intradermal Mycobacterium tuberculosis. This startling result emphasizes just how carefully we must tread in this field, for most clinicians, trained with the idea of indomethacin as an anti-inflammatory agent, would have predicted exactly the opposite effect.
In normal humans, there has been no observed equivalent effect of indomethacin on skin test responses to mumps, candida and trychophyton.6 However, responses to an Influenza A vaccine were enhanced by pretreatment with indomethacin in normal volunteers. This only occurred in strains to which the individual had been previously sensitized, suggesting that PG synthetase inhibitors may act to stimulate the secondary rather than the primary repsonse.'3
How might prostaglandins act?
While it is clear from the above experiments that PGs may have effects, whether major or minor, on in vitro and in vivo measures of immunity, there are a number of issues raised, perhaps the most important of which is how they might act.
The major PG producing cell amongst the mononuclear class is glass-adhe'rent, and it is generally thought that the most important of these is the macrophage. 7 This, by secreting PGE, may either directly suppress T cells or activate a non-glass adherent T suppressor subset (which does not act through prostaglandins). The exact mechanism involved in this immunosuppression is not clear, but is thought to involve both reduced IL2 secretion and IL2 responsiveness.8 PGs exert their effect through cyclic AMP within the cell9 and it is of note that indomethacin may have effects on levels of this metabolite directly via phosphodiesterase inhibition and may also act on cyclic AMP dependent protein kinase. In other words, indomethacin may have immunomodulatory effects independently of PG inhibition and this should be borne in mind in interpretation of in vitro and in vivo work.
Another complicating issue in understanding PG action is that of the effects of leukotrienes on the immune response. There is in vitro evidence that leukotrienes, notably L TB 4 , have antagonistic effects to PGs in immunity: Iipoxygenase products stimulate mitogen-induced proliferation, which is inhibited by lipoxygenase pathway inhibitors. One effect of PG synthetase inhibitors may be, therefore, to channel more arachidonic acid into the Iipoxygenase pathway, as has been proposed in aspirin-induced asthma. ' This mechanistic approach takes us away from the problem of the biological function of PGs in immunity. While we are used to the idea of positive fe edback in the inflammatory response, if tissue damage is to be limited there must also be negative fe edback between the inflammatory and immune cells. Within the immune system, T suppressor cells and idiotypic networks have been proposed to fill such a role. Perhaps PGs, while enhancing the local inflammatory response act to damp the escalation of the developing immune reaction, by fe edback inhibition. If this model is true, two predictions can be made. Firstly, we will only be able to fu lly understand the role of PGs if we consider the immune and inflammatory responses together, not in isolation. Secondly, there may be disease states in which over-or under-damping occurs, leading to hypo-or hyper-responsiveness.
Prostaglandins and abnormal immunity
There is evidence that PGs may play a part in various disease states with disordered immunity. In patients with Hodgkin's Disease, for example, where there is reduced cell-mediated immunity, T suppressor cells are found to produce fo ur times the normal quantity of PGE. In vitro, this suppressive effect can be overcome with indomethacin." In tumour-bearing mice, tumour-induced immunosuppression may be reversed with indomethacin both in vitro and in vivo. Indomethacin not only reduces the rate of tumour growth, but also enhances the therapeutic effect of BeG .'2 Perhaps the most fa scinating experiment in this area has been that concerning the effects of indomethacin on 2 patients with common variable immunodeficiency, a disease associated with abnormal T suppressor function.13 These patients were previously anergic to skin testing with antigens including PPD (purified protein derivative from TB), but showed a return to skin test responsiveness and restoration of in vitro markers of cellular immunity upon drug therapy (disappearing on stopping the drug). This result, although on a small scale, suggests that such immunomodulation may be of clinical significance in situations where the immune system is 'overdamped'. A similar experiment in AIDS patients would be obviously worthwhile, although the underlying pathology is different.
While there is no such profound immunodeficiency disorder in leprosy, there is a precedent for PG-I]1ediated specific immune unresponsiveness in infectious disease. PGs have been implicated in chronic fungal infections, TB, and brucella.3 Treatment of mice infected with Schistosoma mansoni with synthetic PGE led to a significant reduction in the development of egg-induced granulomas.15 These granulomas result from an immune-mediated hypersensitivity response-PGE had no effect on the development of non-immunological foreign body granulomas. Lymphocyte unresponsive ness in Q fever (caused by the organism Coxiella burneti) has been shown to be mediated by PGE I . Here, antigen-specific T suppressor cells appear to secrete an unidentified factor enhancing PGE production by monocytes. 16 Interestingly, antigen-specific T suppressor activity has also been implicated in leprosyY
Prostaglandins in leprosy
Leprosy is a spectrum of diseases caused by a single organism. The position in the spectrum, from the lepromatous pole to the tuberculoid pole, depends on the host immune response. In vitro tests of lymphocyte responsiveness mirror clinical and histopathological indicators of the disease state. 18 The role of immune suppression in determining this response has been studied in some depth, although exactly which cells are involved and how they act is not yet clear.
Nath and colleagues in India have been searching for a monocyte derived suppressor factor; although this has not yet been isolated, its production does not appear to be inhibited by indomethacin, and its physical characteristics make it unlikely to be a PG.19,20 Such a fa ctor may act directly to inhibit IL2 production in T cells oflepromatous patients, although alternative (and more complex) models exist.8,21 One study,22 for example, found that the ability of lepromin to induce suppression of in vitro mitogen responsiveness was mediated by two groups of cells, an adherent cell (assumed to be a macrophage) and a non-adherent T cell.
Other groups have attempted to answer directly the question of whether PGs are involved in the immune response of leprosy. One study23 looked at the effect of PG synthetase inhibition on responsiveness ofT cells from normals and leprosy patients from the lepromatous and tuberculoid poles. They fo und that the unresponsiveness of BLjLL patients was not affected by indomethacin, whereas there was an approximate doubling of in vitro immune reactivity in TTjBT patients. This suggests that PGs are unlikely to be involved in vitro in the hyporesponsiveness of BLjLL patients. Similarly, it also provokes the idea that it might be possible to enhance further the immune responsiveness of BTjTT patients using indomethacin. Interestingly, one study3 noted that cells become more responsive to PG-induced immunosuppression in the presence of low concentrations of antigen, which would be the case in BTjTT individuals.
One study,24 using a guinea-pig M, leprae granuloma model and cell sorter found no detectable PGE in the supernatant of cultures of stimulated granuloma cells. This suggests that the demonstrated inability of these granuloma macro phages to act as accessory cells in immune responses25 is not due to excess PG production, Thus in vitro evidence would point against an important role for PGs in the immunosuppression ofleprosy. While a study of in vivo effects ofPG synthetase inhibitors in leprosy has not been fo und, there may be circumstantial evidence from a study of the effects of other drugs.
Anti-leprosy drugs and prostaglandins
Drugs involved in the treatment of leprosy may have immunopharmacological effects over and above their antimicrobial action. This may occur either indirectly, through changes in antigen load, or directly via intrinsic immunomodulatory activity. 26 As it stands, none of these mechanisms have been proven in vivo, but there is some in vitro evidence in the cases of dapsone and c1ofazimine. Dapsone has known anti-oxidant properties and may be a weak inhibitor of PG synthesis.27 It has been suggested26 that it may act as an immunostimulant through its inhibition of autoregulatory PGs, e.g. there may be an increase in lepromin reaction with dapsone therapy. This is currently a matter for debate, for while it is known that reversal reactions, flare-ups of hypersensitivity in patients with borderline disease, may be precipitated by treatment, one study28 has provided evidence that dapsone in high doses may have a protective effect. However, so little is known about the aetiology of reversal reactions that to draw any conclusions as to the potential role ofPGs from these observations is rather difficult.
Clofazimine (or Lamprene), on the other hand, has been claimed to act as an immunosuppres sant, inhibiting reversal reactions, and inhibiting in vitro markers of lymphocyte reactivity. 29 Anderson has suggested that c10fazimine and dapsone are mutually antagonistic with respect to PG production, the former having pro-oxidant effect, and therefore enhancing PG production. An interesting example of c1ofazimine-induced oxidation is the deposition of ceroid, a substance thought to result from lipid peroxidation and condensation, in a patient on such therapy.3o While these arguments are attractive, they provide only indirect evidence for a role for PGs in leprosy, since these drugs have many other actions.
Lipids and leprosy
Another intriguing insight into the potential effect of drugs on immunity comes from experiments31 with Chaulmoogra and other oils. Chaulmoogra oil had been used for many years in the treatment ofleprosy, taken 'internally, externally and eternally'. Its mode of action is unknown, but is thought to be due to the action of fatty acids of high melting point (hydnocarpic, and chaulmoogric). His account of the effect of such oil on a patient is interesting: 'There was ... thickening of the tissues, fe brile reaction ... swelling up and softening with subsequent more rapid resorption of the lesions. ' This sounds very much like an 'upgrading reversal reaction' using modern terminology. This could, of course, be explained through a release of antigen as a result of antimicrobial activity, but Rogers then went on to perform similar experiments with fish oils (cod-liver oil). He reports 51 cases treated with cod-liver oil alone, of whom 80% improved or cleared, and 65% cleared completely over the course of I year. Rogers notes that the oil appears to have no direct effect on the mycobacteria themselves.
How might these oils be acting? I propose that it may be via an inhibitory action on PG synthesis. It is known that eicosapentenoic acid (EPA) found in fish oils inhibits the synthesis of and is poorly synthesized to PGS.32.33 Indeed, increase of EPA in the diet may lead to an increase in mitogen-induced lymphocyte responsiveness via PG depletion. EPA derived from fish oil is one example of an 'n-3' fatty acid-and it is suggested that all lipids in this group may be inhibitors of PG synthesis.34 Linolenic acid, for example, may have a 'restraining' effect on PGE metabolism. 35 Inhibition of PG synthesis by EPA in fish oil may cause immunostimulation, therefore through release of suppressor activity and promote resolution of leprosy lesions. Hydnocarpic acid itself may also have a weak antioxidant effect by virtue of its resonance hybrid fo rms (Carpenter K., pers. comm .). It would be of great interest to know the effects of this and other oils on PG synthesis in normals and leprosy patients. The original experiments may be over 60 years old, but we may still have something to learn from them.
Prostaglandins in leprosy: a synthesis
There is good evidence that PGs are involved in regulation of the normal immune response, and that they may play a part in various disease states. There is little evidence as yet, however, that they are important in leprosy. This question is not purely academic. We have cheap and reliable anti prostaglandin agents available which could be of use in this disease. I would like to consider two possible situations.
PGs are relevant to the immune defect in leprosy. In this case, there is a chance that PG synthetase inhibitors may accelerate a cure in concert with current anti leprosy drugs. This may be restricted to certain areas of the leprosy spectrum, or certain stages of the disease. The effect on reversal reactions is also unpredictable, since we do not understand their basis. Immunotherapy for leprosy of this kind is not such a far-fetched idea, for this is effectively what is being attempted with the BCG vaccine.
2 PGs are irrelevant to the immune defect in leprosy. In this case, our hopes of immunomodula tion with simple drugs such as aspirin are dashed. There may, however, be an important role for antiprostaglandins as anti-inflammatory agents. In reversal reactions, this is a sudden flare-up of hypersensitivity, as discussed, and this is accompanied by oedema fo rmation within the lesions. Such oedema within a nerve sheath may lead to irreversible ischaemic damage. Currently, emergency treatment for these reactions relies on steroids, which are powerful but dangerous drugs, particularly in the hands of those with little experience in their use. Simple anti-inflammatory agents may be very useful in these situations to counteract the critical oedema, and ifindeed it does turn out that these drugs have few immunostimulant properties (which might provoke or potentiate the reaction), a trial of their use may be warranted.
A scheme for the fu rther investigation of the role of PGs in leprosy is set out below:
EXPT. 
